Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: February 2009
-
American Conference Institute (ACI) will be holding its 5th Annual Document Management, E-Discovery, and Litigation Readiness for Life Sciences conference from March 24, 2009 in New York, NY. The conference will provide information on: • Implementing an effective litigation hold on ESI — and auditing compliance;• Gathering and monitoring e-data stored on multiple databases in…
-
Law Seminars International (LSI) will be holding a one-day workshop on Current Strategies for Patent Claim Construction: Key Updates on Patent Prosecution and Litigation on March 13, 2009 in San Francisco, CA. The workshop will address: • The latest on managing patent drafting;• Case law overview on patent claim interpretation;• Judicial perspective on patent claim…
-
By Kevin E. Noonan — An astute reader has asked, regarding our post concerning EXACT Sciences' announcement of the issuance of U.S. Patent No. 7,485,420, whether the claims of the '420 patent would be invalid under the Federal Circuit's In re Bilski standard for patentable subject matter. The independent claims of the '420 patent…
-
By Donald Zuhn — Yesterday, Senator Herb Kohl (D-WI) (at right) introduced the Preserve Access to Affordable Generics Act (S. 369) in the Senate. The bill, which is co-sponsored by Senators Sherrod Brown (D-OH), Richard Durbin (D-IL), Russell Feingold (D-WI), and Chuck Grassley (R-IA), is designed to prohibit brand name drug companies from compensating…
-
By Sherri Oslick — EXACT Sciences Corp. announced today the issuance of U.S. Patent No. 7,485,420, entitled "Methods and Compositions for Detecting Colon Cancers," which is directed toward the use of differentially methylated vimentin as a marker of colorectal cancer. The patent is assigned to Case Western Reserve University, and licensed exclusively by EXACT…
-
By Donald Zuhn — Last fall, the U.S. Patent and Trademark Office announced that it was seeking up to a thousand registered practitioners to help with a pilot test of the Office's new online Continuing Education for Practitioners (CEP) system (see "Patent Office Seeking Volunteers to Test Continuing Education System"). Yesterday, the Patent Office…
-
By Kevin E. Noonan — Perhaps the most beautiful sentence in scientific literature is this one: It has not escaped our notice that the specific pairing we have postulated immediately suggests a possible copying mechanism for the genetic material. James Watson & Francis Crick, "Molecular Structure of Nucleic Acids; A Structure for Deoxyribose Nucleic…
-
By Suresh Pillai — Oxford Gene Technology Settles Legal Action with Bioarray Solutions On January 21, 2009, Oxford, UK-based Oxford Gene Technology (OGT) announced a settlement of the patent infringement lawsuit OGT filed against BioArray Solutions, Ltd., a subsidiary of Immucor, a U.S. corporation based in Norcross, Georgia (see "Court Report," June 1, 2008). …
-
By Christopher P. Singer — Last week, one of our Japanese associates, Kawaguti & Partners, published a newsletter outlining the impact on foreign applicants that amendments to the Japanese Patent Law will have on patent applications after final rejection. Under the current law, applicants receiving a final rejection have 30 days (plus a 60-day…
-
By Kevin E. Noonan — The correspondence between a nucleic acid sequence and its encoded amino acid sequence is the basis for a great deal of how the U.S. Patent and Trademark Office examines biotechnology claims. In many instances the Office treats these sequences differently. For example, it is common practice for the Office…
Patent Docs 